| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNIP2 |
| Uniprot No | Q8NFZ5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-429aa |
| 氨基酸序列 | MSRDPGSGGW EEAPRAAAAL CTLYHEAGQR LRRLQDQLAA RDALIARLRA RLAALEGDAA PSLVDALLEQ VARFREQLRR QEGGAAEAQM RQEIERLTER LEEKEREMQQ LLSQPQHERE KEVVLLRRSM AEGERARAAS DVLCRSLANE THQLRRTLTA TAHMCQHLAK CLDERQHAQR NVGERSPDQS EHTDGHTSVQ SVIEKLQEEN RLLKQKVTHV EDLNAKWQRY NASRDEYVRG LHAQLRGLQI PHEPELMRKE ISRLNRQLEE KINDCAEVKQ ELAASRTARD AALERVQMLE QQILAYKDDF MSERADRERA QSRIQELEEK VASLLHQVSW RQDSREPDAG RIHAGSKTAK YLAADALELM VPGGWRPGTG SQQPEPPAEG GHPGAAQRGQ GDLQCPHCLQ CFSDEQGEEL LRHVAECCQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNIP2重组蛋白的3篇参考文献示例(虚构内容，仅供参考)：
1. **文献名称**：*"TNIP2 Recombinant Protein Attenuates NF-κB Signaling by Promoting A20 Ubiquitination"*
**作者**：Li, X. et al.
**摘要**：本研究通过表达纯化TNIP2重组蛋白，证明其通过增强A20的泛素化修饰抑制NF-κB通路活性，为炎症性疾病治疗提供潜在靶点。
2. **文献名称**：*"Expression and Functional Analysis of TNIP2 in Autoimmune Disorders"*
**作者**：Chen, Y. & Wang, R.
**摘要**：利用大肠杆菌系统重组表达TNIP2蛋白，发现其通过调控TRAF6降解减少自身免疫反应中的TLR信号过度激活。
3. **文献名称**：*"Structural Characterization of TNIP2 and Its Interaction with TNFAIP3"*
**作者**：Zhang, H. et al.
**摘要**：通过X射线晶体学解析TNIP2重组蛋白结构，揭示其与TNFAIP3结合的关键结构域，阐明两者协同抑制炎症的分子机制。
(注：以上文献为模拟示例，实际文献需通过PubMed或Google Scholar等平台检索确认。)
**Background of TNIP2 Recombinant Protein**
TNIP2 (TNFAIP3-interacting protein 2), also known as ABIN2 (A20-binding inhibitor of NF-κB 2), is a cellular protein involved in regulating inflammatory signaling pathways. It interacts with TNFAIP3 (A20), a key ubiquitin-editing enzyme that suppresses NF-κB activation and inflammation. TNIP2 functions as a co-regulator in A20-mediated inhibition of NF-κB, a transcription factor central to immune responses, apoptosis, and cell survival. Dysregulation of TNIP2 has been implicated in autoimmune diseases, chronic inflammation, and cancer, highlighting its role in maintaining immune homeostasis.
Recombinant TNIP2 protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. The purified protein retains functional domains, including its ubiquitin-binding domain (UBAN), enabling studies on its interaction with ubiquitinated signaling molecules like A20. RIPK1. or TRAF6. Researchers utilize TNIP2 recombinant protein to dissect its molecular mechanisms in vitro, such as its ability to modulate NF-κB signaling, suppress pro-inflammatory cytokine production, or influence cell death pathways.
Beyond basic research, TNIP2 recombinant protein holds therapeutic potential. It serves as a tool for drug screening to identify compounds that enhance or mimic its anti-inflammatory activity. Additionally, it aids in structural studies to map interaction sites for targeted drug design. Its role in diseases like lupus, rheumatoid arthritis, and psoriasis further drives interest in developing TNIP2-based biologics or biomarkers. Overall, TNIP2 recombinant protein is a critical reagent for unraveling immune regulation mechanisms and advancing translational applications in inflammation-related disorders.
×
